Effectiveness and safety of switching biologics after secukinumab treatment failure in moderate-to-severe plaque psoriasis: a retrospective cohort study

1

The study evaluated the safety and efficacy of switching to ixekizumab, guselkumab, or ustekinumab after secukinumab failure in 59 patients.
2

Ixekizumab showed significantly higher PASI 75 response rates at week 12 compared to guselkumab and ustekinumab, with rates of 66.7%, 28.1%, and 16.7%, respectively.
3

In the secondary failure subgroup, ixekizumab demonstrated a numerical advantage in PASI 75 response rates at all time points, though not statistically significant.
4

Adverse event rates were similar among the three biologics, with all events being mild and not requiring treatment discontinuation.
5

The choice of switching strategy should consider the type of treatment failure, patient preference, and specific drug characteristics.

Frontiers In Medicine

by Zhongyu Zhang, Bin Zhang, Yating Wen, Qian Hu, Wenjun Jiang, Jia Zhuo, Guangying Luo, Yuyi Wang
July 6, 2026

1